Le Lézard
Classified in: Covid-19 virus
Subject: RCL

Dr. Reddy's Recalls Prescription Drug Blister Packages Due to Risk of Poisoning


WASHINGTON, Feb. 25, 2021 /PRNewswire/ -- https://cpsc.gov/Recalls/2021/Dr-Reddys-Recalls-Prescription-Drug-Blister-Packages-Due-to-Risk-of-Poisoning

Recall Summary

Name of Products: Imatinib Mesylate Tablets 100 mg, Imatinib Mesylate Tablets 400 mg, Pregabalin Capsules 50 mg, Pregabalin Capsules 75 mg, Pregabalin Capsules 100 mg, Pregabalin Capsules 150 mg, Sevelamer Carbonate Tablets 800 mg, Tadalafil Tablets 5 mg and Tadalafil Tablets 20 mg

Hazard: The products are prescription medications that were labeled and distributed by Dr. Reddy's for institutional use only.  The prescription medications were distributed by third party wholesalers to retail pharmacies and could have been dispensed to consumers.  The packaging of the products is not child resistant and can pose a risk of poisoning if the contents are swallowed by young children.

Remedy: Refund

Consumers should immediately store the recalled medications in a safe location out of reach of children and contact Dr. Reddy's for a full refund.

Consumer Contact:
Dr. Reddy's toll-free at 888-375-3784 from 8 a.m. to 8 p.m. ET Monday through Friday, or online at www.drreddys.com and click on "Recall" for more information.  Report incidents related to children accessing or ingesting these prescription medications to www.SaferProducts.gov.  Report adverse events, medication errors, and quality problems related to the use of these products to FDA's MedWatch Adverse Event Reporting Program either online at www.fda.gov/medwatch/report.htm, download the form at www.fda.gov/MedWatch/getforms.htm or call 800-332-1088 to request a reporting form, then complete and submit by regular mail, and return to the address on the pre-addressed form, or submit by fax to 800-FDA-0178.

Recall Details

Units: About 21,400

Description:
This recall involves blister packages of prescription medications.  The name and strength of the medication, "For Institutional Use only," "Rx Only," lot number and expiration date are printed on the outside of the package as well as on the individual blister units.  The Dr. Reddy's logo and NDC number are printed on the outside of the package.  The recalled medications include the following:

Recalled
Prescription
Drugs

NDC Numbers

Carton
Configurations

Lot Numbers

Expiration
Dates

Imatinib
Mesylate Tablets
100 mg

43598-344-31

 

3 blister cards of
10 tablets

 

H2000138

 

2022-0630

Imatinib
Mesylate Tablets
400 mg

43598-345-31

3 blister cards of
10 tablets

H2000127

2022-0630

Pregabalin

Capsules 50 mg

43598-292-66

5 blister cards of
10 capsules

T900876

2021-0630

Pregabalin
Capsules 75 mg

43598-293-66

5 blister cards of
10 capsules

T901021

2021-0731

Pregabalin

Capsules 100 mg

43598-294-66

5 blister cards of
10 capsules

T901022

2021-0731

Pregabalin

Capsules 150 mg

43598-295-66

5 blister cards of
10 capsules

T901023

2021-0731

Sevelamer
Carbonate

Tablets 800 mg

55111-789-11

4 blister cards of
25 tablets

T801003,
T000009,
T900221

2020-1031,
2021-1231,
2021-0228

Tadalafil

Tablets 5 mg

43598-575-31

3 blister cards of
10 tablets

T000376

2022-0131

Tadalafil

Tablets 20 mg

43598-573-31

3 blister cards of
10 tablets

T000425

2022-0228

Incidents/Injuries: No incidents or injuries have been reported.

Sold At: Beginning in 2018, Dr. Reddy's sold the recalled medications to wholesalers.  Ultimately, these medications could have been sold to consumers at retail pharmacies in the United States at prices varying based on quantities prescribed, health insurance terms, and other factors.

Importer: Dr. Reddy's Laboratories, Inc., of Princeton, N.J.

Manufacturer: Dr. Reddy's Laboratories, Ltd., of India

Manufactured in: India

Footer

About the U.S. CPSC
The U.S. Consumer Product Safety Commission (CPSC) is charged with protecting the public from unreasonable risks of injury or death associated with the use of thousands of types of consumer products.  Deaths, injuries, and property damage from consumer product incidents cost the nation more than $1 trillion annually.  CPSC's work to ensure the safety of consumer products has contributed to a decline in the rate of deaths and injuries associated with consumer products over the past 40 years.

Federal law bars any person from selling products subject to a publicly announced voluntary recall by a manufacturer or a mandatory recall ordered by the Commission.

For lifesaving information:
- Visit CPSC.gov.
- Sign up to receive our e-mail alerts.
- Follow us on Facebook, Instagram @USCPSC and Twitter @USCPSC
- Report a dangerous product or a product-related injury on www.SaferProducts.gov.
- Call CPSC's Hotline at 800-638-2772 (TTY 301-595-7054).
- Contact a media specialist

Note:  Due to the extraordinary circumstances surrounding COVID-19, some of the remedies identified in recall press releases may not be available at this time.  Consumers should check with recalling firms for further details.  It is important to remember that CPSC and recalling firms urge consumers not to use recalled products.

Release Number: 21-089

SOURCE U.S. Consumer Product Safety Commission


These press releases may also interest you

19 avr 2024
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

19 avr 2024
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

19 avr 2024
Adyton Resources Corporation  ("Adyton" or the "Company") announces it has closed its previously announced non-brokered private placement offering, pursuant to which it has issued 50,000,000 common shares of the Company ("Shares") at a price of...

19 avr 2024
Building on a successful phase one in which STChealth proved that the Universal Patient Identifier (UPI)?powered by Experian Health's Universal Identity Manager (UIM) and NCPDP Standardstm?can accurately identify patients across multiple datasets in...

19 avr 2024
Lion Group Holding Ltd. ("Lion" or "the Company") , the operator of an all-in-one trading platform that offers a wide spectrum of products and services, today announced that on April 18, 2024, it received a delinquency notification letter from the...

19 avr 2024
Cosmos Health Inc. ("Cosmos Health" or the "Company'') , a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor...



News published on and distributed by: